Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-08-29

FDA Approved: LASTACAFT — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

FDA approved a supplemental application for LASTACAFT (alcaftadine) from Allergan, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lastacaft (Alcaftadine)

Snippet

SUPPL AP for LASTACAFT (ALCAFTADINE)